Clinical trials: Newly Diagnosed Multiple Myeloma
Myeloma, Newly Diagnosed
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
The phase 2 study evaluated the efficacy and safety of bortezomib in combination with lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients who receive lenalidomide,bortezomib, and…
- Conditions
- Myeloma, Newly Diagnosed, High Risk
- Trial name
- NCT03641456
- Testing
- bortezomib, Lenalidomide, Dexamethasone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
PRIMARY STUDY OBJECTIVES To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma…
- Trial name
- NCT00151203
- Testing
- Clarithromycin, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed multiple myeloma.
- Trial name
- NCT07652138
- Testing
- BCMA/CD19-targeted allogeneic CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Multiple Myeloma
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
The study is designed as a randomized, controlled, open-label, assessor blind, multicenter superiority trial with three parallel groups, and primary endpoint of immunophenotypic complete responses at 18 months after…
- Trial name
- NCT03742297
- Testing
- Lenalidomide., Carfilzomib, Bortezomib
- Where
- 58 sites in Spain
- Volunteers
- 462 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma (MM)
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
- Trial name
- LINKER-MM8 (NCT07428369)
- Testing
- Linvoseltamab, Bortezomib, Lenalidomide
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, DRD
A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients
The goal of this study is to observe and evaluate the incidence of infection in newly diagnosed, non-transplanted multiple myeloma patients receiving prophylactic treatment with sulpegfilgrastim (a pegylated recombinant human…
- Conditions
- Multiple Myeloma, DRD, Sulpegfilgrastim, Neutropenia
- Trial name
- NCT07018271
- Testing
- sulpegfilgrastim
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma, Renal Impairment
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
This is an Investigator-Initiated, phase 2, prospective, open-label study designed to be conducted in six hospitals in Greece. Eligible patients will initially receive an induction phase of six 28-day cycles of isatuximab in…
- Conditions
- Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type
- Trial name
- NCT05147493
- Testing
- Isatuximab, Bortezomib, Cyclophosphamide
- Where
- 6 sites in Greece
- Volunteers
- 51 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma
Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
This clinical trial is a multicenter, cohort, with one arm to study the SLP to 18 months of Velcadito scheme (velcade 1.0 mg / m2 administered over two days with melphalan and prednisone) in patients with MM diagnosis again…
- Trial name
- Velcadito (NCT02773550)
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Basque Health Service
Multiple Myeloma
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
The primary purpose of this study is to estimate the overall response rate (ORR), defined as partial response (PR) or better at any time during induction therapy.
- Trial name
- NCT01729338
- Testing
- Velcade, Cyclophosphamide, Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth…
- Trial name
- NCT00438841
- Testing
- bortezomib, cyclophosphamide, dexamethasone
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with…
- Trial name
- LINKER-MM4 (NCT05828511)
- Testing
- Linvoseltamab
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
- Trial name
- FIRST (NCT00689936)
- Testing
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Where
- 288 sites in United States, Australia and 17 more
- Volunteers
- 1,623 people
- Sponsor
- Celgene
Myeloma
REal World MAIA UK OutcomEs
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated…
- Trial name
- REMAKE (NCT07532473)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Multiple Myeloma
Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma…
- Trial name
- STOMP (NCT02343042)
- Testing
- Selinexor, Dexamethasone, Lenalidomide
- Where
- 25 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Karyopharm Therapeutics Inc
Multiple Myeloma
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
- Trial name
- NCT00057564
- Testing
- A (Thalidomide + Dexamethasone)
- Where
- 99 sites in United States, Australia and 14 more
- Volunteers
- 470 people
- Sponsor
- Celgene Corporation
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Trial name
- NCT04566328
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 647 sites in United States, Puerto Rico
- Volunteers
- 1,450 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Plasma Cell Leukemia (PCL)
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
The goal of this clinical trial is to learn whether CM336, a BCMA/CD3 bispecific antibody, can improve treatment outcomes when combined with isatuximab, lenalidomide, and bortezomib in adults with newly diagnosed primary plasma…
- Trial name
- CAREMM-011 (NCT07652905)
- Testing
- CM336, Isatuximab, Bortezomib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies side effects and how well bendamustine hydrochloride, bortezomib, and dexamethasone work in treating patients with newly diagnosed multiple myeloma.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT02224729
- Testing
- Bendamustine hydrochloride, Bortezomib, Dexamethasone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Multiple Myeloma
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received…
- Trial name
- NCT01029054
- Testing
- carfilzomib, lenalidomide plus dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreased bone formation leading to…
- Trial name
- NCT00376883
- Testing
- pamidronate
- Where
- 14 sites in Denmark, Norway and 1 more
- Volunteers
- 500 people
- Sponsor
- Nordic Myeloma Study Group